Envision Report

Published January 10, 2018

North America Diabetes Drugs Market – Size, Outlook, Trends and Forecasts (2018 – 2024)

Download Free Sample Report!

Diabetes is often referred by doctors as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body’s cells do not respond properly to insulin or both. Patients with high blood sugar typically experience polyuria (frequent urination), and become increasingly thirsty (polydipsia) and hungry (polyphagia).

North America Diabetes Drugs Market Share:

Oral Diabetic Medication Drugs segment is expected to hold the largest share in the North American Diabetes Drugs Market in the forecast period 2018-2014.

North America Diabetes Drugs Market Size:

The North America diabetes drugs market, valued as a USD 12.38 billion markets in 2018, is expected to grow at an exponential rate and become a USD 17.82 billion market by 2024, at a CAGR of about 7.69%.

North American Diabetes Drugs market holds the major share in the world market scenario. In North America, USA and Canada have the largest market share. The market is valued at $12.38 billion in 2018 and is expected to reach $17.82 billion by the end of 2024 with a CAGR of 7.69%.

North America Diabetes Drugs Market Growth:

Rise in the number of diabetics, Complexities in alternative diabetic therapies, Strong encouragement from the governments are the major factors that are driving the growth of the market.

North America Diabetes Drugs Market Industry Analysis:

The market is segmented on the basis of diabetic drugs, devices, and geography. The diabetic drugs market is again segmented into categories, which are insulin derivatives and oral diabetic medication drugs.

North America Diabetes Drugs Market Outlook:

The Diabetes market has undergone a dynamic shift over the past decade, primarily due to the entry of three new non-insulin drug classes for T2DM: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose linked transporter 2 (SGLT-2) inhibitors.

North America Diabetes Drugs Market Trends:

Abbott had announced that the FreeStyle Libre System, the company’s revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS). Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour.

North America Diabetes Drugs Market Research report includes:

  • An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
  • To have complete market analysis through industry value chain analysisPorter’s fivePESTLESWOT analysis, and Y-o-Y analysis.
  • Regional and global diversity is analyzed with the major countries and the unions. Scrutinizing the revenue generation on YearOnYear
  • Identifying DROCin the current market and their impact in altering the market dynamics.
  • Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with major competitors.
  • Expertise investment opportunities by an analyst to the individual and organization to have a better foothold in the market.
  • Identify the latest developments, market shares and strategies that are employed by the major market players, such as
  • Abbott Laboratories
  • Accu-Chek
  • Arkray USA
  • Bayer
  • Lilly Diabetes

Chapter 1 Introduction

1.1 Executive Summary

1.2 Market Definition

1.3 Scope of  the Study

Chapter 2 Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.3 Analytic Tools and Model

2.4 Economic Indicator

2.4.1 Base Year, Base Currency, Forecasting Period

2.5 Expert Validation

2.6 Study Timeline

Chapter 3 Market Analysis

3.1 Industry Value Chain Analysis

3.2 Porter’s Five Analysis

3.2.1 Bargaining Power of Buyers

3.2.2 Bargaining Power of Suppliers

3.2.3 Threats of Substitutes

3.2.4 Threats of New Entrants

3.2.5 Industry Rivalry

3.3 PESTLE Analysis

3.3.1 Political

3.3.2 Economical

3.3.3 Social

3.3.4 Technological

3.3.5 Legal

3.3.6 Environmental

3.4 SWOT Analysis

3.4.1 Strengths

3.4.2 Weakness

3.4.3 Opportunities

3.4.4 Threat

3.5 Y-O-Y Analyses

Chapter 4 Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

Chapter 5 Market Segmentation Analysis        

Chapter 6 Market Segmentation, By Drugs 

     6.1 Insulin Derivatives

6.1.1  Long-acting insulin

6.1.2 Intermediate-acting insulin

6.1.3 Rapid-acting insulin

6.2 Oral Diabetic Medication Drugs

6.2.1 GPP4-Inhibitors

6.2.2 Meglitinides

6.2.3 Biguanide

6.2.4 Thiazolidinediones

6.2.5 Alpha-Glucosidase inhibitor

6.2.6  Metformin

6.2.7 Sulfonylurea

Chapter 7 Market Segmentation, By Geography

7.1 Introduction

7.2 USA

7.3  Canada

7.4  Mexico

Chapter 8 Competitive Landscape

8.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements

8.2  Market Share Analysis

8.3 Strategies Adopted By Top Companies

Chapter 9 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

9.1. Merck & Co.

9.1.1. Company Overview

9.1.2. Financial Performance

9.1.3. Product Benchmarking

9.1.4. Strategic Initiative

9.2. Johnson & Johnson

9.3. Dexcom Inc

9.4. Abbott Laboratories

9.5. Accu-Chek

9.6. Arkray USA

9.7. Bayer

9.8. Lilly Diabetes

9.9. Animas

9.10. SmithsMedical Deltec

9.11. Disetronic/Roche Insulin Delivery Systems

9.12. Novonordisk

9.13. Sanofi

9.14. Eli Lilly and Company

9.15. LifeScan

Chapter 11 Market Estimates and Forecast

11.1   Market Estimates and Forecast 2018-2024(USD Million)

11.1.1 Market Estimation and Forecast by Drugs 2018-2024 (USD Million)

11.1.2 Market Estimates and Forecast by Geography 2018-2024 (USD Million)

Chapter 12 Market Insights

12.1 Insights of Industry Experts

13.2 Analyst Opinion (Market Understanding)

13.3 Investment Opportunities

Chapter 14 Appendix

14.1 List of Tables

14.2 List of Figures

  • Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
  • Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
  • The Regional and Global Variety is taken care of in the report.
  • Year on Year basis generation of revenue is studied.
  • Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
  • The overview and the sustainability of the market are analyzed through SWOT.
  • DROC is recognized in the current market scenario and see how its effect on market dynamics.
  • The segment-level analysis in terms of type and technology.
  • The value chain analysis, value that's created and captured by a company is the profit margin.Value
  • Created and Captured – Cost of Creating that Value = Margin
  • An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
  • Basis on the depth of the study we approach using analytical tools
  • Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.

 

©2018 - Envision Inteligence | All Rights Reserved.